卵母细胞
生物信息学
生物
医学
治疗方法
心理干预
线粒体
生殖医学
神经科学
辅助生殖技术
胚胎干细胞
转化研究
重症监护医学
能力(人力资源)
干预(咨询)
作者
Raziye Melike Yildirim,Gizem Nur Şahin,Richard T. Scott,Emre U Seli
出处
期刊:Human Reproduction
[Oxford University Press]
日期:2026-08-03
卷期号:41 (9): 1497-1506
被引量:2
标识
DOI:10.1093/humrep/deag118
摘要
Mitochondria are central to oocyte competence and early embryonic development, with roles that extend beyond energy production to include regulation of redox homeostasis, apoptosis and cellular aging. Mitochondrial dysfunction is increasingly recognized as a key contributor to diminished ovarian reserve, impaired embryo development, and accelerated reproductive aging. Mitochondria-targeted therapeutic strategies, including pharmacological approaches such as Coenzyme Q10, mitoquinone, resveratrol, rapamycin, and NAD+ precursors, as well as mitochondrial replacement techniques such as maternal spindle and pronuclear transfer, have shown promise in preclinical models; however, clinical outcomes remain heterogeneous and often inconclusive. This translational gap likely reflects critical limitations, including variability in therapeutic targets, suboptimal timing of intervention relative to oocyte development, and insufficiently powered or standardized clinical studies. Greater emphasis on well-defined, physiologically justified therapeutic targets, along with the use of physiologically relevant experimental systems, may improve therapeutic precision and efficacy. Rigorous evaluation of safety, particularly for interventions with pleiotropic effects or heritable consequences, remains essential. A more targeted, developmentally informed and systematically validated approach is needed to advance mitochondria-based therapies toward meaningful improvements in reproductive outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI